ArticleEukaryotic cell2007
Genome-wide expression and location analyses of the Candida albicans Tac1p regulon.
Article in Eukaryotic cell, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 128 citations in OpenAlex.
- Deciphering the multidrug resistance paradigm inAntimicrobial agents and chemotherapy · 2026Review
- Article
- Mutations inAntimicrobial agents and chemotherapy · 2025Article
- A Comprehensive Analysis of the Lipidomic Signatures inJournal of fungi (Basel, Switzerland) · 2024Article
- The zinc cluster transcription factor Znc1 regulates Rta3-dependent miltefosine resistance inmSphere · 2024Article
- Fungal Drug Response and Antimicrobial Resistance.Journal of fungi (Basel, Switzerland) · 2023Review
- Evaluation of virulence factors and azole resistance mechanisms ofIranian journal of microbiology · 2023Article
- Molecular dissection studies ofFrontiers in microbiology · 2023Article
- Expression pattern of drug-resistance genes ERG11 and TAC1 in Candida albicans Clinical isolates.Molecular biology reports · 2022Article
- A Proteomic Landscape of Candida albicans in the Stepwise Evolution to Fluconazole Resistance.Antimicrobial agents and chemotherapy · 2022Article
- Participation of the ABC TransporterJournal of fungi (Basel, Switzerland) · 2021Article
- Ethylzingerone, a Novel Compound with Antifungal Activity.Antimicrobial agents and chemotherapy · 2021Article
- Hyperexpression of CDRs and HWP1 genes negatively impacts on Candida albicans virulence.PloS one · 2021Article
- Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis.Frontiers in cellular and infection microbiology · 2021Review
- High-Resolution Genome-Wide Occupancy inmSphere · 2020Article
- Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans.The Journal of antimicrobial chemotherapy · 2020Review
- mSphere of Influence: Decoding Transcriptional Regulatory Networks To Illuminate the Mechanisms of Microbial Pathogenicity.mSphere · 2020Article
- Review
- Role of lipid transporters in fungal physiology and pathogenicity.Computational and structural biotechnology journal · 2019Review
- A Hyperactive Form of the Zinc Cluster Transcription Factor Stb5 CausesAntimicrobial agents and chemotherapy · 2018Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 3 countries.
Funding
Abstract
A major mechanism of azole resistance in Candida albicans is overexpression of the genes encoding the ATP binding cassette transporters Cdr1p and Cdr2p due to gain-of-function mutations in Tac1p, a transcription factor of the zinc cluster family. To identify the Tac1p regulon, we analyzed four matched sets of clinical isolates representing the development of CDR1- and CDR2-mediated azole resistance by using gene expression profiling. We identified 31 genes that were consistently up-regulated with CDR1 and CDR2, including TAC1 itself, and 12 consistently down-regulated genes. When a resistant strain deleted for TAC1 was examined similarly, expression of almost all of these genes returned to levels similar to those in the matched azole-susceptible isolate. Using genome-wide location (ChIP-chip) analysis (a procedure combining chromatin immunoprecipitation with hybridization to DNA intergenic microarrays), we found 37 genes whose promoters were bound by Tac1p in vivo, including CDR1 and CDR2. Sequence analysis identified nine new genes whose promoters contain the previously reported Tac1p drug-responsive element (CGGN(4)CGG), including TAC1. In total, there were eight genes whose expression was modulated in the four azole-resistant clinical isolates in a TAC1-dependent manner and whose promoters were bound by Tac1p, qualifying them as direct Tac1p targets: CDR1, CDR2, GPX1 (putative glutathione peroxidase), LCB4 (putative sphingosine kinase), RTA3 (putative phospholipid flippase), and orf19.1887 (putative lipase), as well as IFU5 and orf19.4898 of unknown function. Our results show that Tac1p binds under nonactivating conditions to the promoters of its targets, including to its own promoter. They also suggest roles for Tac1p in regulating lipid metabolism (mobilization and trafficking) and oxidative stress response in C. albicans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.